Results 211 to 220 of about 27,004 (255)
Some of the next articles are maybe not open access.
Hematology, 2003
AbstractThe last decade has witnessed a multistep evolution in the understanding of the natural history, clinical manifestations, and some of the molecular mechanisms that underlie the ineffective hematopoiesis and leukemic transformation in the myelodysplastic syndrome (MDS).
Mufti, G, List, A F, Gore, S D, Ho, A Y
openaire +2 more sources
AbstractThe last decade has witnessed a multistep evolution in the understanding of the natural history, clinical manifestations, and some of the molecular mechanisms that underlie the ineffective hematopoiesis and leukemic transformation in the myelodysplastic syndrome (MDS).
Mufti, G, List, A F, Gore, S D, Ho, A Y
openaire +2 more sources
Current Opinion in Hematology, 1995
Myelodysplastic syndrome continues to present a formidable clinical challenge. Despite considerable effort, no therapy apart from allogeneic bone marrow transplantation has been shown to prolong survival. Lack of effective therapy for myelodysplastic syndrome is of further concern given recent reports on the high incidence of myelodysplastic syndrome ...
R D, Legare, D G, Gilliland
openaire +2 more sources
Myelodysplastic syndrome continues to present a formidable clinical challenge. Despite considerable effort, no therapy apart from allogeneic bone marrow transplantation has been shown to prolong survival. Lack of effective therapy for myelodysplastic syndrome is of further concern given recent reports on the high incidence of myelodysplastic syndrome ...
R D, Legare, D G, Gilliland
openaire +2 more sources
Hematology, 2002
AbstractThe myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency associated with cytopenias leading to serious morbidity plus the additional risk of leukemic transformation. Therapeutic dilemmas exist in MDS because of the disease’s multifactorial pathogenetic features, heterogeneous stages, and the patients’ generally elderly
Peter L, Greenberg +2 more
openaire +2 more sources
AbstractThe myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency associated with cytopenias leading to serious morbidity plus the additional risk of leukemic transformation. Therapeutic dilemmas exist in MDS because of the disease’s multifactorial pathogenetic features, heterogeneous stages, and the patients’ generally elderly
Peter L, Greenberg +2 more
openaire +2 more sources
Expert Opinion on Biological Therapy, 2007
The myelodysplastic syndrome(s) (MDS), bone marrow stem cell malignancies that share pathogenetic overlap with acute myeloid leukemia, are characterized by peripheral blood cytopenias and, in more advanced subtypes, varied degrees of maturation arrest. Premature apoptosis of bone marrow cellular elements contributes to ineffective hematopoiesis, which ...
openaire +2 more sources
The myelodysplastic syndrome(s) (MDS), bone marrow stem cell malignancies that share pathogenetic overlap with acute myeloid leukemia, are characterized by peripheral blood cytopenias and, in more advanced subtypes, varied degrees of maturation arrest. Premature apoptosis of bone marrow cellular elements contributes to ineffective hematopoiesis, which ...
openaire +2 more sources
Pathology Patterns Reviews, 2003
Myelodysplastic syndromes are a group of clonal hematopoietic stem cell disorders in which there is ineffective hematopoiesis. Affected patients are primarily elderly people, but also at risk are certain subsets of patients who have been exposed to antineoplastic chemotherapy and select patients with primary bone marrow failure syndromes such as ...
Phuong L, Nguyen, Yin, Xu, Aminah, Jatoi
openaire +2 more sources
Myelodysplastic syndromes are a group of clonal hematopoietic stem cell disorders in which there is ineffective hematopoiesis. Affected patients are primarily elderly people, but also at risk are certain subsets of patients who have been exposed to antineoplastic chemotherapy and select patients with primary bone marrow failure syndromes such as ...
Phuong L, Nguyen, Yin, Xu, Aminah, Jatoi
openaire +2 more sources
International Journal of Hematology, 2005
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of
Shinji, Nakao +5 more
openaire +4 more sources
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of
Shinji, Nakao +5 more
openaire +4 more sources
Hematology/Oncology Clinics of North America, 2009
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders that affect mostly the elderly and have a variable probability of progression to acute leukemia. The diagnosis of MDS rests largely on a critical morphologic review of blood and bone marrow slides, with careful correlation with other clinical and essential laboratory ...
openaire +2 more sources
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders that affect mostly the elderly and have a variable probability of progression to acute leukemia. The diagnosis of MDS rests largely on a critical morphologic review of blood and bone marrow slides, with careful correlation with other clinical and essential laboratory ...
openaire +2 more sources
Current Treatment Options in Oncology, 2000
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders with a variable clinical course and prognosis. Treatment should be individualized based on the patient's age, subtype, percent blasts in the marrow, and cytogenetics. The use of the International Prognostic Scoring Index is helpful in assigning prognosis.
openaire +2 more sources
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders with a variable clinical course and prognosis. Treatment should be individualized based on the patient's age, subtype, percent blasts in the marrow, and cytogenetics. The use of the International Prognostic Scoring Index is helpful in assigning prognosis.
openaire +2 more sources
Annual Review of Medicine, 2010
Myelodysplastic syndromes (MDS) represent a collection of stem cell disorders characterized by impaired hematopoiesis resulting in low peripheral blood counts. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death.
Bart L, Scott, H Joachim, Deeg
openaire +2 more sources
Myelodysplastic syndromes (MDS) represent a collection of stem cell disorders characterized by impaired hematopoiesis resulting in low peripheral blood counts. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death.
Bart L, Scott, H Joachim, Deeg
openaire +2 more sources
Current Opinion in Hematology, 1996
Myelodysplasia is being increasingly recognized as an important disease not only in the elderly but also in younger patients. It is also being seen more commonly as a complication of treatment with chemotherapeutic agents. Recent advances have distinguished between the different forms of therapy-related myelodysplasia as well as their genetic ...
openaire +2 more sources
Myelodysplasia is being increasingly recognized as an important disease not only in the elderly but also in younger patients. It is also being seen more commonly as a complication of treatment with chemotherapeutic agents. Recent advances have distinguished between the different forms of therapy-related myelodysplasia as well as their genetic ...
openaire +2 more sources